JP2002205949A - Method for ameliorating dysbolism and composition therefor - Google Patents

Method for ameliorating dysbolism and composition therefor

Info

Publication number
JP2002205949A
JP2002205949A JP2001000184A JP2001000184A JP2002205949A JP 2002205949 A JP2002205949 A JP 2002205949A JP 2001000184 A JP2001000184 A JP 2001000184A JP 2001000184 A JP2001000184 A JP 2001000184A JP 2002205949 A JP2002205949 A JP 2002205949A
Authority
JP
Japan
Prior art keywords
level
concentrate
suppressing
composition
total cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001000184A
Other languages
Japanese (ja)
Other versions
JP4393717B2 (en
Inventor
Futoshi Matsuyama
太 松山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YUUSU TECHNO CORP KK
Original Assignee
YUUSU TECHNO CORP KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YUUSU TECHNO CORP KK filed Critical YUUSU TECHNO CORP KK
Priority to JP2001000184A priority Critical patent/JP4393717B2/en
Publication of JP2002205949A publication Critical patent/JP2002205949A/en
Application granted granted Critical
Publication of JP4393717B2 publication Critical patent/JP4393717B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for suppressing insulin value, total cholesterol value or neutral fat value in human blood for a person having the high values thereof and to provide a method for the suppression. SOLUTION: The composition consists essentially of a concentrate of a hot water extract or an alcohol extract from a dried leaf of Lagerstroemia Speciosa, Linn and the concentrate has 0.1-15 mg content of corosolic acid based on 100 mg of the concentrate. The composition is used for suppressing and ameliorating dysbolism values such as the insulin value, total cholesterol value and neutral fat value in the human blood. The method for inhibiting the values by administering the composition is provided.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明はヒトの血中における
インシュリン値、総コレステロール値あるいは中性脂肪
値を抑制する方法並びにそのための組成物に関する。さ
らに詳しくはヒトの血中におけるインシュリン値、総コ
レステロール値あるいは中性脂肪値が正常値よりも高い
人に対して、バナバ葉からの特定の抽出濃縮物を投与し
これらの値を抑制する方法並びにそのための組成物に関
する。
The present invention relates to a method for suppressing insulin, total cholesterol, or triglyceride in human blood and a composition therefor. More specifically, insulin levels in human blood, total cholesterol levels or triglyceride levels are higher than normal levels, and a method for suppressing these levels by administering a specific extract concentrate from banaba leaves and It relates to a composition therefor.

【0002】[0002]

【従来の技術】バナバ葉[Lagerstroemia
Speciosa、 Linn.または Pers.]
は、フトモモ目ミソハギ科に属し、通称オオバナサルス
ベリとも称され、フィリピンを始め、インド、マレーシ
ア、中国南部およびオーストラリアなどの東南アジアに
広く生育している。殊にフィリピンでは古来乾燥したバ
ナバ葉や花を煎じて飲用されている。この飲用物は、糖
尿病の民間治療剤としても広く知られている。
2. Description of the Related Art Banaba leaves [ Lagerstroemia ]
Speciosa , Linn. Or Pers.]
Is a member of the family Myrtiniidae, commonly known as the Oleander sedge, and grows widely in Southeast Asia, including the Philippines, India, Malaysia, southern China, and Australia. Especially in the Philippines, dried banaba leaves and flowers have been infused since ancient times. This drink is also widely known as a folk remedy for diabetes.

【0003】このバナバ葉に着目し、そのバナバ葉のエ
キスを分析していくつかの成分を取り出し、その1つの
成分としてコロソリン酸(Corosolic Aci
d)が存在すること、このコロソリン酸は、エールリッ
ヒ腹水腫瘍細胞(Ehrlich Ascites T
umour Cells)を使用して、その活性を調べ
た所、ブドウ糖移動の賦活物質であることが報告されて
いる[Chem. Pharm. Bull. 41(1
2)2129−2131(1993)]。この報告は、
インビトロでの実験結果であり、コロソリン酸の抗糖尿
病作用の第1段階の判別検査の結果を示唆しているに過
ぎない。
[0003] Focusing on this banaba leaf, the extract of the banaba leaf is analyzed to extract several components, and corosolic acid (Corosolic Aci) as one of the components.
d) is present, and this corosolic acid is associated with Ehrlich Ascites T cells.
When its activity was examined using Umour Cells, it was reported to be an activator of glucose transfer [Chem. Pharm. Bull. 41 (1)
2) 2129-2131 (1993)]. This report,
The results of in vitro experiments only suggest the results of the first-stage discriminative test of the antidiabetic effect of corosolic acid.

【0004】一方特開平5−310587号公報には、
バナバ葉を熱水あるいは有機溶媒で抽出した濃縮乾燥物
(バナバ抽出粉末エキス)を成分とする抗糖尿病剤が提
案されている。この提案は、バナバ葉の抽出液から水溶
性画分並びに脂溶性画分を取り出して、粉末エキスとす
ることにより簡便で安全性の高い抗糖尿病剤としたもの
である。同公報には、粉末エキスを例えば2%濃度に希
釈して飲用する態様が推奨され、その抗糖尿病作用は、
糖尿病マウスを用いた動物実験で確認している。
On the other hand, JP-A-5-310587 discloses that
There has been proposed an antidiabetic agent comprising a concentrated dried product (banaba extract powder extract) obtained by extracting banaba leaves with hot water or an organic solvent. In this proposal, a water-soluble fraction and a fat-soluble fraction are extracted from a banaba leaf extract and made into a powder extract to obtain a simple and highly safe antidiabetic agent. In this publication, an embodiment in which a powder extract is diluted to a concentration of, for example, 2% and drinkable is recommended.
It has been confirmed in animal experiments using diabetic mice.

【0005】前述したように乾燥バナバ葉は、民間療法
として糖尿病治療に効果があるとして利用されていた
が、バナバ葉の如何なる成分がヒト抗糖尿病作用に活性
を有しているかは明確に知られていない。コロソリン酸
が1成分として含有されていることは知られているが、
その活性も細胞を使用したインビトロにおけるブドウ糖
移動の賦活作用を調べた結果に過ぎない。また、バナバ
葉の抽出物中如何なる成分がヒトの抗糖尿病治療に活性
を有しているかについて具体的に臨床試験で確認された
知見は存在しない。その上バナバ葉の抽出成分と、血糖
値上昇作用との関係についても従来調べられた知見は見
当らない。
[0005] As described above, dried banaba leaves have been used as a folk remedy for treating diabetes, but it is clearly known what components of banaba leaves have activity in human anti-diabetic activity. Not. It is known that corosolic acid is contained as one component,
The activity is also merely the result of examining the activity of glucose transfer in vitro using cells. In addition, there is no specific confirmation in clinical trials as to which component in the extract of banaba leaf has an activity in treating human anti-diabetes. In addition, there has been no finding of a relationship between an extract component of banaba leaf and a blood sugar level increasing effect.

【0006】そこで本発明者は、バナバ葉の抽出物中の
成分とヒトの血糖値の上昇あるいは抑制との関係を臨床
実験に基づいて調べた。空腹時の血糖値が約110mg
/dlよりやや高い軽症糖尿病患者であって、インシュ
リン非依存型の患者に対して、バナバ葉の抽出濃縮物で
あって、コロソリン酸を或る特定割合含有する組成物を
投与すると、血糖値の上昇が抑制されかつ平均的に低下
が確認された。また本発明者の研究によれば、前記コロ
ソリン酸を一定割合含有する組成物は、乾燥したバナバ
葉を一定条件下で抽出、濃縮及び乾燥することにより得
られることが判明した。そこで本発明者は、前記知見に
基づいて、乾燥したバナバ葉の熱水抽出物もしくはアル
コール抽出物の濃縮物を主成分とし、該濃縮物100m
g当たりコロソリン酸含有量が0.1〜15mgであ
る、血糖値上昇乃至下降用組成物を提供した。
Therefore, the present inventor examined the relationship between the components in the extract of banaba leaf and the increase or suppression of the blood glucose level in humans based on clinical experiments. About 110mg fasting blood sugar
/ Dl, a patient with mild diabetes and a non-insulin-dependent patient, is administered a composition containing a specific proportion of corosolic acid, which is a banaba leaf extract concentrate, The rise was suppressed and a decrease was confirmed on average. According to the study of the present inventor, it has been found that the composition containing the corosolic acid at a certain ratio can be obtained by extracting, concentrating and drying dried banaba leaves under certain conditions. Therefore, based on the above findings, the present inventor has made a concentrated hot water extract or alcohol extract of dried banaba leaves as a main component, and the concentrate 100 m
A composition for increasing or decreasing blood glucose level, wherein the content of corosolic acid per gram is 0.1 to 15 mg.

【0007】[0007]

【発明が解決しようとする課題】本発明者は、バナバ葉
の前記濃縮物の他の作用について研究を進めたところ、
ヒトの血中におけるインシュリン値、総コレステロール
値あるいは中性脂肪値が正常値よりも高い人に対して、
前記濃縮物を投与すると、これらの値が抑制されること
が判明し本発明に到達した。すなわち前記代謝異常に対
して改善される組成物として有効であることが見出され
た。
SUMMARY OF THE INVENTION The present inventor has conducted research on other effects of the concentrate of banaba leaves,
For those whose insulin, total cholesterol or triglyceride levels in human blood are higher than normal,
The administration of the concentrate was found to suppress these values, and reached the present invention. That is, it has been found that the composition is effective as a composition for improving the metabolic abnormality.

【0008】[0008]

【課題を解決するための手段】かくして本発明によれ
ば、下記1〜10の発明が提供される。 1.乾燥したバナバ葉の熱水抽出物もしくはアルコール
抽出物の濃縮物を主成分とし、該濃縮物はその100m
g当りコロソリン酸含有量が0.1〜15mgである、
代謝異常改善用組成物。 2.インシュリン値抑制、総コレステロール値抑制また
は中性脂肪値抑制のための1項記載の代謝異常改善用組
成物。 3.インシュリン値抑制のための1項記載の組成物。 4.総コレステロール値抑制のための1項記載の組成
物。 5.中性脂肪値抑制のための1項記載の組成物。 6.(1)血中のインシュリン値が正常値よりも高い
人、(2)血中の総コレステロール値が正常値よりも高
い人あるいは(3)血中の中性脂肪値が正常値よりも高
い人に、1項記載の濃縮物を経口投与することを特徴と
する、インシュリン値、総コレステロール値あるいは中
性脂肪値を抑制する方法。 7.体重1kg当りかつ1日当り50mg〜1000m
gの濃縮物を投与する6項記載の方法。 8.血中のインシュリン値が18μU/ml以上である
人に、1項記載の濃縮物を、体重1kg当りかつ1日当
り50mg〜1000mg経口投与することを特徴とす
るインシュリン値の抑制方法。 9.血中の総コレステロール値が220mg/dl以上
である人に、1項記載の濃縮物を、体重1kg当りかつ
1日当り50mg〜1000mg経口投与することを特
徴とする総コレステロール値の抑制方法。 10.血中の中性脂肪値が150mg/dl以上である
人に、1項記載の濃縮物を、体重1kg当りかつ1日当
り50mg〜1000mg経口投与することを特徴とす
る中性脂肪値の抑制方法。
According to the present invention, the following 1 to 10 inventions are provided. 1. Concentrate of hot water extract or alcohol extract concentrate of dried banaba leaves as the main component, the concentrate is 100 m
corosolic acid content per g is 0.1 to 15 mg,
A composition for improving metabolic abnormality. 2. 2. The composition for improving metabolic abnormality according to claim 1, for suppressing insulin level, total cholesterol level or neutral fat level. 3. 2. The composition according to claim 1, for inhibiting an insulin level. 4. 2. The composition according to claim 1, for suppressing total cholesterol level. 5. 2. The composition according to claim 1, which is used for suppressing a neutral fat level. 6. (1) A person whose blood insulin level is higher than a normal value, (2) A person whose blood total cholesterol level is higher than a normal value, or (3) A person whose blood triglyceride level is higher than a normal value A method for suppressing insulin level, total cholesterol level or neutral fat level, which comprises orally administering the concentrate according to claim 1. 7. 50mg-1000m / kg body weight / day
7. The method according to claim 6, wherein the concentrate is administered. 8. A method for suppressing insulin levels, comprising orally administering a concentrate according to claim 1 to a person whose blood insulin level is 18 μU / ml or more, at a dose of 50 mg to 1000 mg per kg of body weight and per day. 9. A method for suppressing total cholesterol, which comprises orally administering the concentrate according to claim 1 to a person having a blood total cholesterol of 220 mg / dl or more, at a dose of 50 mg to 1000 mg per kg of body weight and per day. 10. A method for suppressing a neutral fat value, comprising orally administering a concentrate according to claim 1 to a person having a blood neutral fat value of 150 mg / dl or more, at a dose of 50 mg to 1000 mg per 1 kg body weight and per day.

【0009】コロソリン酸(corosolic ac
id)は下記の構造式で表されるトリテルペノイド類化
合物の一種である。
[0009] Corosolic acid (corosolic acid)
id) is a kind of triterpenoid compound represented by the following structural formula.

【0010】[0010]

【化1】 Embedded image

【0011】本発明の組成物におけるヒトの血中のイン
シュリン値、総コレステロール値あるいは中性脂肪値の
抑制作用は、濃縮物中のコロソリン酸の特定割合の含有
及び乾燥バナバ葉の他の抽出成分の相互作用に起因して
いるものと考えられる。本発明の組成物の原料として使
用されるバナバ葉は、フィリピンなどで産出するバナバ
(Lagerstroemia Speciosa、
Linn. またはPers.)の生葉を乾燥したもので
ある。生葉の乾燥は自然乾燥または風乾乃至強制乾燥の
いずれであってもよい。乾燥は、いわゆるトーステッド
ドライにより水分含量が20重量%以下、好ましくは1
0重量%以下となるように行うのが、微生物の生育を防
止しかつ保存安定性のために望ましい。乾燥したバナバ
葉は、そのまま抽出してもよいが粉砕または細断して抽
出することが望ましい。
The inhibitory effect of the composition of the present invention on the insulin level, total cholesterol level or triglyceride level in human blood is due to the inclusion of a specific proportion of corosolic acid in the concentrate and other extracted components of dried banaba leaves. It is thought to be due to the interaction of Banaba leaves used as a raw material of the composition of the present invention are banaba (Lagerstroemia Speciosa,
Linn. Or Pers.). Drying of fresh leaves may be either natural drying or air drying or forced drying. Drying is performed by so-called toasted drying, wherein the water content is 20% by weight or less, preferably 1% by weight.
It is desirable to perform the treatment so as to be 0% by weight or less for preventing the growth of microorganisms and for preservation stability. The dried banaba leaf may be extracted as it is, but it is desirable to extract it by crushing or shredding.

【0012】本発明において乾燥したバナバ葉を熱水も
しくはアルコール抽出し、濃縮する方法および条件は特
に制限されるわけではないが、濃縮物中にコロソリン酸
が一定の割合で含有されるような方法および条件を採用
すべきである。すなわち、濃縮物(乾燥固形物)100
mg当たり、コロソリン酸が0.1〜15mgの割合で
含有する濃縮物であるのが望ましい。コロソリン酸の含
有割合は、濃縮物100mg当たり、0.2〜12mg
が好ましく、0.5〜10mgが特に好ましい。さらに
本発明の組成物は、コロソリン酸以外の他の成分も活性
に影響を与えているから、抽出成分および濃縮の方法お
よび条件は、他の成分の含有についても考慮されるべき
であり、その好適な方法および条件については後述する
説明から、その好ましい態様が理解される。
In the present invention, the method and conditions for extracting dried banaba leaves by hot water or alcohol extraction and concentrating are not particularly limited, but a method in which corosolic acid is contained in the concentrate at a certain ratio. And conditions should be adopted. That is, the concentrate (dry solid) 100
It is desirable that the concentrate is 0.1 to 15 mg of corosolic acid per mg. The content ratio of corosolic acid is 0.2 to 12 mg per 100 mg of the concentrate.
Is preferable, and 0.5 to 10 mg is particularly preferable. Furthermore, since the composition of the present invention also affects the activity of components other than corosolic acid, the extraction components and the method and conditions for concentration should be considered for the content of other components. Preferred embodiments will be understood from the following description of preferred methods and conditions.

【0013】方法1:この方法は、乾燥したバナバ葉の
粉砕化物(原料)をエタノールまたはエタノール水溶液
(エタノール含量50〜80重量%)を原料に対して5
〜20重量倍、好ましくは8〜10重量倍に加えて、常
温〜90℃好ましくは約50〜85℃の温度で30分〜
2時間加熱還流する。この抽出を2〜3回繰り返す。得
られた抽出液に、随意原料に対して5〜10重量%の活
性炭を加えて脱色することができる。脱色は、本発明の
組成物の食品などへの応用範囲を拡大するのに役立つ。
次いで濾過して60℃以下の温度で減圧下濃縮し、得ら
れた固形状物を50〜70℃の温度で減圧下(濃縮より
も高い減圧下)にて乾燥する。かくして得られた固形物
を粉砕して粉末状濃縮物を得る。このような方法で得ら
れた濃縮物は、コロソリン酸を所定量含有し、その上そ
の他の成分も有効量含有したものとなる。
Method 1: In this method, pulverized dried banaba leaf (raw material) is prepared by adding ethanol or an aqueous ethanol solution (ethanol content of 50 to 80% by weight) to the raw material.
20 to 20 times by weight, preferably 8 to 10 times by weight, at room temperature to 90 ° C, preferably at a temperature of about 50 to 85 ° C for 30 minutes to
Heat to reflux for 2 hours. This extraction is repeated 2-3 times. The obtained extract can be decolorized by adding 5 to 10% by weight of activated carbon to the optional raw material. Decolorization is useful for expanding the application range of the composition of the present invention to foods and the like.
Then, the mixture is filtered and concentrated under reduced pressure at a temperature of 60 ° C. or lower, and the obtained solid is dried at a temperature of 50 to 70 ° C. under reduced pressure (under reduced pressure higher than concentration). The solid thus obtained is ground to obtain a powdery concentrate. The concentrate obtained by such a method contains a predetermined amount of corosolic acid and also contains other components in effective amounts.

【0014】方法2:この方法は、メタノールまたはメ
タノール水溶液を用いて抽出する方法である。この方法
は原料に対して3〜20重量倍のメタノールまたはメタ
ノール水溶液(メタノール含量50〜90重量%)を用
いて抽出する。抽出操作は、常温〜65℃の範囲の温度
で30分〜2時間実施するのが好適である。抽出操作は
1回に限らず2回以上繰り返して行うことができる。得
られた抽出液は所望により脱色して、前記方法1と同様
の条件で濃縮して固形物を得ることができる。
Method 2: This method is an extraction method using methanol or an aqueous methanol solution. In this method, extraction is performed using 3 to 20 times by weight of methanol or an aqueous methanol solution (methanol content of 50 to 90% by weight) based on the raw material. The extraction operation is preferably performed at a temperature in the range of room temperature to 65 ° C. for 30 minutes to 2 hours. The extraction operation can be performed not only once but also repeatedly two or more times. The obtained extract may be decolorized if desired and concentrated under the same conditions as in Method 1 to obtain a solid.

【0015】方法3:この方法3は熱水を用いた抽出方
法である。原料に対して3〜20重量倍の熱水を使用
し、50〜90℃、好ましくは60〜85℃の温度で3
0分〜2時間抽出操作を行う。抽出後の濃縮および乾燥
は、濃縮物が高い温度で長時間保持されると活性成分が
劣化することがあるので比較的短時間で行うことが望ま
しい。そのために減圧下にて濃縮および乾燥を行うのが
有利である。前記した方法1〜3は、基本的な方法およ
び条件を説明するためのものであり、これらの改変や組
合せを適宜行うことも可能である。例えば、方法1およ
び方法2を組み合わせて実施することもできる。これら
の方法のうち、好ましいのは方法1および方法2であ
り、特に好ましいのは方法1である。
Method 3: This method 3 is an extraction method using hot water. Use hot water 3 to 20 times the weight of the raw material, and heat at a temperature of 50 to 90 ° C, preferably 60 to 85 ° C.
Perform the extraction operation for 0 minutes to 2 hours. Concentration and drying after the extraction are desirably performed in a relatively short time because the active ingredient may be deteriorated if the concentrate is kept at a high temperature for a long time. For this purpose, it is advantageous to carry out concentration and drying under reduced pressure. The above-mentioned methods 1 to 3 are for explaining the basic methods and conditions, and these modifications and combinations can be appropriately performed. For example, the method 1 and the method 2 can be implemented in combination. Of these methods, methods 1 and 2 are preferred, and method 1 is particularly preferred.

【0016】本発明の組成物は、体重1kg当りかつ1
日当り、50mg〜1000mg、好ましくは70mg
〜800mg経口投与される。特に経口投与は、1日に
2〜3回に分けて行うのが好ましい。さらに投与は少な
くとも1ヶ月、より好ましくは少なくとも3ヶ月継続す
るのが望ましい。本発明の組成物は、粉末状もしくは顆
粒状の形態であることができる。またペレットもしくは
カプセル化剤のような錠剤の形態であってもよい。
The composition of the present invention contains 1
50 mg to 1000 mg, preferably 70 mg per day
~ 800 mg orally. In particular, oral administration is preferably performed twice or three times a day. Further, it is desirable that the administration last for at least one month, more preferably at least three months. The composition of the present invention can be in the form of powder or granules. It may be in the form of a tablet such as a pellet or an encapsulating agent.

【0017】[0017]

【実施例】以下実施例を掲げて本発明をさらに具体的に
説明する。 参照例1 (1) 乾燥バナバ葉からの濃縮物の調製 フィリピン産の乾燥バナバ葉1kgを切断し80重量%
エタノール水溶液5リットル中に入れ加熱還流下(約8
5℃)にて1.5時間抽出操作を行った。抽出後バナバ
葉を濾別し、再び80重量%エタノール水溶液中に入
れ、加熱還流下(約85℃)にて1.5時間抽出操作を
行いバナバ葉を濾別した。1回目および2回目の抽出液
を合わせて500gの活性炭を加えて脱色処理を行っ
た。活性炭を除去した後、60℃減圧下にエタノールお
よび水を除去して濃縮物を得た。次いで60℃にてさら
に減圧下に保持して乾燥固形物を得た。この固形物を粉
砕して粉末濃縮物150gを得た。 (2) コロソリン酸の分析 前記(1)で得られた粉末状の濃縮物1gをメタノール
10mlに溶解し、高性能液体クロマトグラフ(HPL
C)にて分析したところ、コロソリン酸(coroso
lic acid)が前記濃縮物当たり30mg(濃縮
物100mg当たり3mgに相当)含有されていた。 (3)錠剤の調製 前記(1)で得られた粉末状の濃縮物を用いて下記組成
の臨床試験用の錠剤を作った。
The present invention will be described in more detail with reference to the following examples. Reference Example 1 (1) Preparation of concentrate from dried banaba leaves 1 kg of dried banaba leaves from the Philippines was cut and 80% by weight
Put into 5 liters of aqueous ethanol solution and heat to reflux (about 8
(5 ° C.) for 1.5 hours. After the extraction, the banaba leaves were separated by filtration, put again in an 80% by weight aqueous ethanol solution, and subjected to an extraction operation under heat reflux (about 85 ° C.) for 1.5 hours to filter the banaba leaves. The decolorization treatment was performed by adding 500 g of activated carbon to the first and second extraction liquids in total. After removing the activated carbon, ethanol and water were removed under reduced pressure at 60 ° C. to obtain a concentrate. Then, it was further kept under reduced pressure at 60 ° C. to obtain a dry solid. This solid was pulverized to obtain 150 g of a powder concentrate. (2) Analysis of corosolic acid 1 g of the powdery concentrate obtained in (1) above was dissolved in 10 ml of methanol, and the solution was subjected to high performance liquid chromatography (HPL).
C), corosolic acid (corosoric acid)
lic acid) was contained at 30 mg per concentrate (equivalent to 3 mg per 100 mg concentrate). (3) Preparation of tablet Using the powdery concentrate obtained in the above (1), a tablet for a clinical test having the following composition was prepared.

【0018】 組成 重量% 粉末状濃縮物 50 食物繊維*1 20 しょ糖脂肪酸エステル 3 乳糖 22 硬化油*2 100 * 1は結晶セルロースを使用した * 2はナタネ硬化油を使用した 前記組成を均一に混合して打錠機にて1錠が250mg
の錠剤(“A錠”という)を調製した。
Composition% by weight Powdered concentrate 50 Dietary fiber * 1 20 Sucrose fatty acid ester 3 Lactose 22 Hardened oil * 2 5 100 * 1 uses crystalline cellulose * 2 uses rapeseed hardened oil Mix and use a tableting machine to weigh 250 mg per tablet.
Tablets (referred to as "A tablets").

【0019】実施例1 血中のインシュリン値が18μU/ml以上であるヒト
5人に対して、0週から4週間の間1日3回食後に1人
当り毎回A錠を3錠コップ一杯の水で飲用させた。投与
開始時および4週間経過時に採血し、血中のインシュリ
ン値を調べた。その結果を下記表1に示した。
Example 1 For five humans whose blood insulin level is 18 μU / ml or more, three A tablets per day after meal three times a day from week 0 to 4 weeks. Drink with water. Blood was collected at the start of administration and at the lapse of 4 weeks, and the insulin level in the blood was examined. The results are shown in Table 1 below.

【0020】[0020]

【表1】 [Table 1]

【0021】血中の総コレステロール値が220mg/
dl以上であるヒト7人に対して、0週から4週間の間
1日3回食後に1人当り毎回A錠を3錠コップ一杯の水
で飲用させた。投与開始時および4週間経過時に採血
し、血中の総コレステロール値を調べた。その結果を下
記表2に示した。
The total cholesterol level in the blood is 220 mg /
Seven humans dl or more were allowed to drink three A tablets each time with a glass of water each time after eating three times a day for 0 to 4 weeks. Blood was collected at the start of administration and at the lapse of 4 weeks, and the total cholesterol level in blood was examined. The results are shown in Table 2 below.

【0022】[0022]

【表2】 [Table 2]

【0023】血中の中性脂肪値が150mg/dl以上
であるヒト12人に対して、0週から4週間の間1日3
回食後に1人当り毎回A錠を3錠コップ一杯の水で飲用
させた。投与開始時および4週間経過時に採血し、血中
の中性脂肪値を調べた。その結果を下記表3に示した。
For 12 humans whose blood triglyceride level is 150 mg / dl or more, 3
After the meal, each person was drunk with 3 tablets of A tablet each time with a glass of water. Blood was collected at the start of administration and at the lapse of 4 weeks, and the triglyceride level in the blood was examined. The results are shown in Table 3 below.

【0024】[0024]

【表3】 [Table 3]

Claims (10)

【特許請求の範囲】[Claims] 【請求項1】 乾燥したバナバ葉の熱水抽出物もしくは
アルコール抽出物の濃縮物を主成分とし、該濃縮物はそ
の100mg当りコロソリン酸含有量が0.1〜15m
gである、代謝異常改善用組成物。
1. A concentrate comprising a hot water extract or an alcohol extract of dried banaba leaves as a main component, the concentrate having a corosolic acid content of 0.1 to 15 m / 100 mg.
g, a composition for improving metabolic abnormality.
【請求項2】 インシュリン値抑制、総コレステロール
値抑制または中性脂肪値抑制のための請求項1記載の代
謝異常改善用組成物。
2. The composition for improving metabolic abnormality according to claim 1, which is for suppressing an insulin level, a total cholesterol level or a neutral fat level.
【請求項3】 インシュリン値抑制のための請求項1記
載の組成物。
3. The composition according to claim 1, for inhibiting an insulin level.
【請求項4】 総コレステロール値抑制のための請求項
1記載の組成物。
4. The composition according to claim 1, for suppressing total cholesterol level.
【請求項5】 中性脂肪値抑制のための請求項1記載の
組成物。
5. The composition according to claim 1, which is used for suppressing a neutral fat level.
【請求項6】 (1)血中のインシュリン値が正常値よ
りも高い人、(2)血中の総コレステロール値が正常値
よりも高い人あるいは(3)血中の中性脂肪値が正常値
よりも高い人に、請求項1記載の濃縮物を経口投与する
ことを特徴とする、インシュリン値、総コレステロール
値あるいは中性脂肪値を抑制する方法。
6. A person whose blood insulin level is higher than a normal value, (2) a person whose blood total cholesterol level is higher than a normal value, or (3) a normal blood triglyceride level. A method for suppressing insulin level, total cholesterol level or triglyceride level, which comprises orally administering the concentrate according to claim 1 to a person having a higher level.
【請求項7】 体重1kg当りかつ1日当り50mg〜
1000mgの濃縮物を投与する請求項6記載の方法。
7. An amount of 50 mg / kg body weight / day
7. The method according to claim 6, wherein 1000 mg of the concentrate is administered.
【請求項8】 血中のインシュリン値が18μU/ml
以上である人に、請求項1記載の濃縮物を、体重1kg
当りかつ1日当り50mg〜1000mg経口投与する
ことを特徴とするインシュリン値の抑制方法。
8. The blood insulin level is 18 μU / ml.
The above-mentioned person, the concentrate of Claim 1 is weighed 1 kg.
A method for suppressing an insulin level, comprising orally administering 50 mg to 1000 mg per day per day.
【請求項9】 血中の総コレステロール値が220mg
/dl以上である人に、請求項1記載の濃縮物を、体重
1kg当りかつ1日当り50mg〜1000mg経口投
与することを特徴とする総コレステロール値の抑制方
法。
9. The total cholesterol level in the blood is 220 mg.
A method for suppressing total cholesterol level, comprising orally administering the concentrate according to claim 1 to a person having a cholesterol concentration of not less than / dl per day and 50 mg to 1000 mg per 1 kg body weight per day.
【請求項10】 血中の中性脂肪値が150mg/dl
以上である人に、請求項1記載の濃縮物を、体重1kg
当りかつ1日当り50mg〜1000mg経口投与する
ことを特徴とする中性脂肪値の抑制方法。
10. The blood has a neutral fat level of 150 mg / dl.
The above-mentioned person, the concentrate of Claim 1 is weighed 1 kg.
A method for suppressing a neutral fat level, comprising orally administering 50 mg to 1000 mg per day per day.
JP2001000184A 2001-01-04 2001-01-04 Metabolic abnormality improving method and composition therefor Expired - Fee Related JP4393717B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001000184A JP4393717B2 (en) 2001-01-04 2001-01-04 Metabolic abnormality improving method and composition therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001000184A JP4393717B2 (en) 2001-01-04 2001-01-04 Metabolic abnormality improving method and composition therefor

Publications (2)

Publication Number Publication Date
JP2002205949A true JP2002205949A (en) 2002-07-23
JP4393717B2 JP4393717B2 (en) 2010-01-06

Family

ID=18869037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001000184A Expired - Fee Related JP4393717B2 (en) 2001-01-04 2001-01-04 Metabolic abnormality improving method and composition therefor

Country Status (1)

Country Link
JP (1) JP4393717B2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255837A (en) * 2001-03-01 2002-09-11 Mikimoto Pharmaceut Co Ltd Aldose reductase inhibitor
WO2005027656A1 (en) * 2003-09-22 2005-03-31 Use-Techno Corporation Functional sweetener
WO2005099486A1 (en) * 2004-04-15 2005-10-27 San-Ei Gen F.F.I., Inc. Process for preparing lagerstroemia speciosa l. extract
JP2005350453A (en) * 2004-05-14 2005-12-22 Toyo Shinyaku:Kk Slightly water-soluble component of leaf of lagerstroemia speciosa l.
JP2006502154A (en) * 2002-09-04 2006-01-19 デーエスエム イーペー アセッツ ベスローテン フェンノートシャップ A nutritional and therapeutic composition comprising an insulin sensitivity enhancer and a peptide fraction
US7071229B2 (en) 2003-06-16 2006-07-04 Tokiwa, Phytochemical Co., Ltd. Process for producing corosolic acid
JP2008505886A (en) * 2004-07-08 2008-02-28 ガンガ, ラジュ ゴカラジュ, A novel structural analog of corosolic acid with anti-diabetic and anti-inflammatory properties
US7534770B2 (en) 2004-03-31 2009-05-19 Morinaga Milk Industry Co., Ltd. Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent
US7674784B2 (en) 2004-09-29 2010-03-09 Morinaga Milk Industry Co., Ltd. Drug and food or drink for improving hyperglycemia
US7754704B2 (en) 2004-03-31 2010-07-13 Morinaga Milk Industry Co., Ltd. Method for treating hyperglycemia

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002255837A (en) * 2001-03-01 2002-09-11 Mikimoto Pharmaceut Co Ltd Aldose reductase inhibitor
JP2006502154A (en) * 2002-09-04 2006-01-19 デーエスエム イーペー アセッツ ベスローテン フェンノートシャップ A nutritional and therapeutic composition comprising an insulin sensitivity enhancer and a peptide fraction
JP4719465B2 (en) * 2002-09-04 2011-07-06 ディーエスエム アイピー アセッツ ビー.ブイ. A nutritional and therapeutic composition comprising an insulin sensitivity enhancer and a peptide fraction
US7071229B2 (en) 2003-06-16 2006-07-04 Tokiwa, Phytochemical Co., Ltd. Process for producing corosolic acid
WO2005027656A1 (en) * 2003-09-22 2005-03-31 Use-Techno Corporation Functional sweetener
JPWO2005027656A1 (en) * 2003-09-22 2007-11-15 株式会社ユース・テクノコーポレーション Functional sweetener
US7754704B2 (en) 2004-03-31 2010-07-13 Morinaga Milk Industry Co., Ltd. Method for treating hyperglycemia
US8486462B2 (en) 2004-03-31 2013-07-16 Morinaga Milk Industry Co., Ltd. Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent
US8338403B2 (en) 2004-03-31 2012-12-25 Morinaga Milk Industry Co., Ltd. Drug for improving hyperglycemia
US7534770B2 (en) 2004-03-31 2009-05-19 Morinaga Milk Industry Co., Ltd. Glycoside having 4-methylergost-7-en-3-ol skeleton and hyperglycemia improving agent
JPWO2005099486A1 (en) * 2004-04-15 2008-03-06 三栄源エフ・エフ・アイ株式会社 Preparation method of banaba extract
JP4688795B2 (en) * 2004-04-15 2011-05-25 三栄源エフ・エフ・アイ株式会社 Preparation method of banaba extract
WO2005099486A1 (en) * 2004-04-15 2005-10-27 San-Ei Gen F.F.I., Inc. Process for preparing lagerstroemia speciosa l. extract
JP2005350453A (en) * 2004-05-14 2005-12-22 Toyo Shinyaku:Kk Slightly water-soluble component of leaf of lagerstroemia speciosa l.
JP2008505886A (en) * 2004-07-08 2008-02-28 ガンガ, ラジュ ゴカラジュ, A novel structural analog of corosolic acid with anti-diabetic and anti-inflammatory properties
JP4732454B2 (en) * 2004-07-08 2011-07-27 ライラ ニュートラシューティカルズ A novel structural analog of corosolic acid with anti-diabetic and anti-inflammatory properties
US7674784B2 (en) 2004-09-29 2010-03-09 Morinaga Milk Industry Co., Ltd. Drug and food or drink for improving hyperglycemia

Also Published As

Publication number Publication date
JP4393717B2 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
JP2000169384A (en) Blood glucose level increase inhibitor or hypoglycemic agent
JP4669920B2 (en) Functional material that suppresses blood glucose rise and blood pressure rise
KR20150058234A (en) Novel extracts of Cynara scolymus, Coffea spp. and Olea europaea for the treatment of metabolic syndrome
JP4393717B2 (en) Metabolic abnormality improving method and composition therefor
JP2011020925A (en) Offal fat-type overweight inhibitor and method for producing the same
WO2012140894A1 (en) Pharmaceutical composition
JP5546039B2 (en) Use of plum extract to produce a composition
JP3302302B2 (en) Antiallergic food
JP2003169621A (en) Tea of momordica charantia and method for producing the same
JP2005089419A (en) Garlic extract
JP2009203209A (en) Composition for blood sugar reduction and/or anti-obesity containing material originated from bark of acacia
JPH1149690A (en) Composition for stimulating lipolysis
JP3142192B2 (en) Blood lipid improving agent and composition containing the same
JP2000342228A (en) Formulated tea of smallanthus sonchifol with mulberry leaf
JP2006016340A (en) Blood uric acid level reduction agent having extract of punica granatum l. as active ingredient
JP7162357B2 (en) Absorption accelerator for cinnamic acid derivatives
JP3936245B2 (en) Antihypertensive
CN110404029B (en) Composition with blood sugar reducing effect and preparation method and application thereof
JP2019064958A (en) Composition for reducing neutral fat and cholesterol
JP4454069B2 (en) Chronic hepatitis inhibitor
FR2931664A1 (en) PLANT COMPOSITIONS AND USES
JP4673474B2 (en) New liver disorder inhibitor
JP2004161721A (en) ANTIOBESITY AGENT, DIET AGENT AND alpha-GLUCOSIDASE INHIBITOR
JP2024079214A (en) Composition having bradycardia improving effect and atrioventricular block improving effect
JP2003176231A (en) Therapeutic and prophylactic composition for diabetes mellitus and its complication

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060814

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061211

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070412

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091014

R150 Certificate of patent or registration of utility model

Ref document number: 4393717

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121023

Year of fee payment: 3

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131023

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees